|
Market Closed -
Nasdaq
20:00:00 26/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 10.00 USD | -0.40% |
|
+16.01% | +29.53% |
| 10-15 | Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says | MT |
| 10-15 | Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.22B | - | - | - | ||
| 65.28B | |||||
| 54.57B | |||||
| 53.59B | |||||
| 45.03B | |||||
| 42.17B |
- Stock Market
- Stocks
- VSTM Stock
- Charts Verastem, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
